Novartis


TeenScreen: Who Pays for Treatment and Drugs?? Sun, 29 May 2005 In her latest examination of the President’s Commission on Mental Health recommendation for universal mental health screening, Evelyn Pringle focuses on the $$$ it costs and on how screening, followed by prescribing psychotropic drugs, is bankrupting of public health […]

TeenScreen: Who Pays for Treatment and Drugs??


Antipsychotic Drug Use Doubled since 1996 in Tennessee Children – Why? Thu, 2 Sep 2004 A Vanderbilt University study found that the use of antipsychotic drugs has doubled among poor children in Tennessee. “The increase, seen largely among children diagnosed with attention-deficit/hyperactivity disorder (ADHD), conduct disorder and affective disorders such […]

Antipsychotic Drug Use Doubled since 1996 in Tennessee Children – ...


How Genentech, Novartis Stifled A Promising Drug – WSJ Tue, 05 Apr 2005 A front page story in The Wall Street Journal should be distributed to every Congress person who will be considering Bioshield II providing yet additional financial incentives and give-a-ways to pharmaceutical companies. The story perfectly illustrates this […]

How Genentech, Novartis Stifled A Promising Drug – WSJ



NY Times Does it Again – Drug Advertisers Get Front Page Coverage to Boost SSRI Market Wed, 2 Jun 2004 The New York Times saw fit to print a report about preliminary, unpublished findings of a study whose authors claim to have “found that Prozac helps teenagers overcome depression far […]

NY Times Does it Again – Drug Advertisers Get Front ...


Drugmakers Go Furthest to Sway Congress: 1,274 Lobbyists – USA Today Tue, 26 Apr 2005 USA Today provides a glimpse into the way the pharmaceutical industry controls health care policy by buying influence at the highest level of government, and underwriting professional and lay healthcare organizations whose spokespersons parrot industry’s […]

Drugmakers Go Furthest to Sway Congress: 1,274 Lobbyists – USA ...


Conflicts of Interest policy – New York Times Sun, 28 Mar 2004 To: ‘Executive-editor@nytimes’; ‘gcollins@nytimes’; ‘arosenthal@nytimes’; ‘pboffey@nytimes’; ‘lchang@nytimes’; ‘oped@nytimes’ Cc: ‘Daniel Okrent’ ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) Promoting openness and full disclosure http://www.ahrp.org FYI Friday’s New York Times included the following Editor’s Note on the paper’s Op Ed page: […]

Conflicts of Interest policy – New York Times



Forbes: Judgment Day for the FDA, Pfizer Wed, 9 Feb 2005 On Feb. 16-18 COX-2 Inhibitor Safety Issues will be the focus of an FDA Advisory Committee and (simultaneously) the European Medicines Agency (EMA). The entire drug industry will be watching with bated breath. Which causal explanation will be offered […]

Forbes: Judgment Day for the FDA, Pfizer


How Did the Vioxx Debacle Happen? USA Today / Lancet Tue, 12 Oct 2004 Dr. Eric Topol of the Cleveland Clinic: “The senior executives at Merck and the leadership at the FDA share responsibility for not having taken appropriate action and not recognizing that they are accountable for the public […]

How Did the Vioxx Debacle Happen? USA Today / Lancet


10 of 32 FDA Vioxx Panelists Had Industry Ties_NYT / Cozy NIH Review “Clears” NIH Industry Ties_WashPost Fri, 25 Feb 2005 The latest example of the corrupting influence of the pharmaceutical industry on health care policy is the composition of FDA’s advisory panel that last week endorsed the marketing of […]

10 of 32 FDA Vioxx Panelists Had Industry Ties / ...